|
1
|
Dempke WC, Suto T and Reck M: Targeted
therapies for non-small cell lung cancer. Lung Cancer. 67:257–274.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Greenlee RT, Hill-Harmon MB, Murray T and
Thun M: Cancer statistics. CA Cancer J Clin. 51:15–36. 2011.
View Article : Google Scholar
|
|
3
|
Gainor JF and Shaw AT: Novel targets in
non-small cell lung cancer: ROS1 and RET fusions. Oncologist.
18:865–875. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Villarreal Garza, de la Mata D, Zavala DG,
Macedo-Perez EO and Arrieta O: Aggressive treatment of primary
tumor in patients with non-small-cell lung cancer and exclusively
brain metastases. Clin Lung Cancer. 14:6–13. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Napolitano LM and Meroni G: TRIM family:
Pleiotropy and diversification through homomultimer and
heteromultimer formation. IUBMB Life. 64:64–71. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hatakeyama S: TRIM proteins and cancer.
Nat Rev Cancer. 11:792–804. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kosaka Y, Inoue H, Ohmachi T, Yokoe T,
Matsumoto T, Mimori K, Tanaka F, Watanabe M and Mori M: Tripartite
motif-containing 29 (TRIM29) is a novel marker for lymph node
metastasis in gastric cancer. Ann Surg Oncol. 14:2543–2549. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Santin AD, Zhan F, Bellone S, Palmieri M,
Cane S, Bignotti E, Anfossi S, Gokden M, Dunn D, Roman JJ, et al:
Gene expression profiles in primary ovarian serous papillary tumors
and normal ovarian epithelium: Identification of candidate
molecular markers for ovarian cancer diagnosis and therapy. Int J
Cancer. 112:14–25. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dyrskjøt L, Kruhøffer M, Thykjaer T,
Marcussen N, Jensen JL, Møller K and Ørntoft TF: Gene expression in
the urinary bladder: A common carcinoma in situ gene expression
signature exists disregarding histopathological classification.
Cancer Res. 64:4040–4048. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Travis WD, Brambilla E, Noguchi M,
Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ,
Van Schil PE, et al: International association for the study of
lung cancer/american thoracic society/european respiratory society
international multidisciplinary classification of lung
adenocarcinoma. J Thorac Oncol. 6:244–285. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Goldstraw P, Crowley J, Chansky K, et al:
International Association for the Study of Lung Cancer
International Staging Committee; Participating Institutions: The
IASLC Lung Cancer Staging Project: Proposals for the revision of
the TNM stage groupings in the forthcoming (seventh) edition of the
TNM Classification of malignant tumours. J Thorac Oncol. 2:706–714.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Groome PA, Bolejack V, Crowley JJ, et al:
The IASLC Lung Cancer Staging Project: Validation of the proposals
for revision of the T, N, and M descriptors and consequent stage
groupings in the forthcoming (seventh) edition of the TNM
classification of Malignant Tumours. J Thorac Oncol. 2:694–705.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kwon MJ, Park S, Choi JY, Oh E, Kim YJ,
Park YH, Cho EY, Kwon MJ, Nam SJ, Im YH, et al: Clinical
significance of CD151 overexpression in subtypes of invasive breast
cancer. Br J Cancer. 106:923–930. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Suzuki S, Miyazaki T, Tanaka N, Sakai M,
Sano A, Inose T, Sohda M, Nakajima M, Kato H and Kuwano H:
Prognostic significance of CD151 expression in esophageal squamous
cell carcinoma with aggressive cell proliferation and invasiveness.
Ann Surg Oncol. 18:888–893. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yuan Z, Villagra A, Peng L, Coppola D,
Glozak M, Sotomayor EM, Chen J, Lane WS and Seto E: The ATDC
(TRIM29) protein binds p53 and antagonizes p53-mediated functions.
Mol Cell Biol. 30:3004–3015. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sho T, Tsukiyama T, Sato T, Kondo T, Cheng
J, Saku T, Asaka M and Hatakeyama S: TRIM29 negatively regulates
p53 via inhibition of Tip60. Biochim Biophys Acta. 1813:1245–1253.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shibata MA, Yoshidome K, Shibata E, Jorcyk
CL and Green JE: Suppression of mammary carcinoma growth in vitro
and in vivo by inducible expression of the Cdk inhibitor p21.
Cancer Gene Ther. 8:23–35. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kanno Y, Watanabe M, Kimura T, Nonomura K,
Tanaka S and Hatakeyama S: TRIM29 as a novel prostate basal cell
marker for diagnosis of prostate cancer. Acta Histochem.
116:708–712. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu J, Welm B, Boucher KM, Ebbert MT and
Bernard PS: TRIM29 functions as a tumor suppressor in
nontumorigenic breast cells and invasive ER+breast cancer. Am J
Pathol. 180:839–847. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fristrup N, Birkenkamp-Demtröder K,
Reinert T, Sanchez-Carbayo M, Segersten U, Malmström PU, Palou J,
Alvarez-Múgica M, Pan CC, Ulhøi BP, et al: Multicenter validation
of cyclin D1, MCM7, TRIM29 and UBE2C as prognostic protein markers
in non-muscle-invasive bladder cancer. Am J Pathol. 182:339–349.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tang ZP, Cui QZ, Dong QZ, Xu K and Wang
EH: Ataxia-telangiectasia group D complementing gene (ATDC)
upregulates matrix metalloproteinase 9 (MMP-9) to promote lung
cancer cell invasion by activating ERK and JNK pathways. Tumour
Biol. 34:2835–2842. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang L, Yang H, Palmbos PL, Ney G, Detzler
TA, Coleman D, Leflein J, Davis M, Zhang M, Tang W, et al:
ATDC/TRIM29 phosphorylation by ATM/MAPKAP kinase 2 mediates
radioresistance in pancreatic cancer cells. Cancer Res.
74:1778–1788. 2014. View Article : Google Scholar : PubMed/NCBI
|
